Onkologie. 2024:18(1):39-42 | DOI: 10.36290/xon.2024.008

Changes in approach to locoregional treatment of early breast cancer

Iveta Kolářová1, 2, 3, Jaroslav Vaňásek3, 4, Igor Sirák1, 2, 3, Kateřina Horáčková3, Denisa Pohanková1
1 Klinika onkologie a radioterapie, FN Hradec Králové
2 Lékařská fakulta, Karlova univerzita v Hradci Králové
3 Fakulta zdravotnických studií, Univerzita Pardubice
4 Multiscan, Pardubice, s. r. o.

Choosing the optimal therapeutic strategy in patients with breast cancer is a challen­ging task. The disease comprises a number of subtypes having distinct biological charac­teristics and variable prognosis, and can occur in elderly women in whom standard therapeutic approaches may result in significant deterioration in their quali­ty of life with no survival benefit. Numerous studies have shown various options for reducing the burden of surgery and radiotherapy not only for the group of patients at early stages of breast cancer. De-escalation of radiotherapy involves omitting radiation in selected patients, shortening the duration of treatment by using hypofractionation and ultra-hypofractionation, and reducing the irradiated volume by partial breast irradiation. It is essential for the patient to be properly informed and to be able to participate in the decision-making process on the therapeutic options.

Keywords: breast cancer, de-escalation, radiotherapy, older age, targeted therapy, toxicity.

Accepted: February 22, 2024; Published: February 28, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolářová I, Vaňásek J, Sirák I, Horáčková K, Pohanková D. Changes in approach to locoregional treatment of early breast cancer. Onkologie. 2024;18(1):39-42. doi: 10.36290/xon.2024.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Národní onkologický registr ČR. ÚZIS ČR; Český statistický úřad; GLOBOCAN 2020, diagnóza C50, počet na 100 000 žen, věkově standardizováno na světový standard. Available from: https://www.uzis.cz/index.php?pg=aktuality&aid=8528.
    2. Tseng J, Bazan JG, Minami CA, et al. Not Too Little, Not Too Much: Optimizing More Versus Less Locoregional Treatment for Older Patients With Breast Cancer. Am Soc Clin Oncol Educ Book. 2023;43:e390450. Go to original source... Go to PubMed...
    3. Bastiaannet E, Liefers GJ, de Craen AJ, et al. Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients. Breast Cancer Res Treat. 2010;124(3):801-807. Go to original source... Go to PubMed...
    4. Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer. 2004;101(6):1302-1310. doi: 10.1002/cncr.20535. PMID: 15316944. Go to original source... Go to PubMed...
    5. Harbeck N, Rastogi P, Martin M, et al. monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571-1581. Go to original source... Go to PubMed...
    6. Schmid P, Cortes J, Pusztai L, et al. KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810-821. Go to original source... Go to PubMed...
    7. Tutt ANJ, Garber JE, Kaufman B, et al. OlympiA Clinical Trial Steering Committee and Investigators. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394-2405. Go to original source... Go to PubMed...
    8. Sacchini V, Norton L. Escalating de-escalation in breast cancer treatment. Breast Cancer Res Treat. 2022;195(2):85-90. Go to original source... Go to PubMed...
    9. Barry M, Levin C, MacCuaig M, et al. Boston ISDM Planning Committee. Shared decision making: vision to reality. Health Expect. 2011;14 Suppl 1(Suppl 1):1-5. Go to original source... Go to PubMed...
    10. Hamelinck VC, Bastiaannet E, Pieterse AH, et al. Preferred and Perceived Participation of Younger and Older Patients in Decision Making About Treatment for Early Breast Cancer: A Prospective Study. Clin Breast Cancer. 2018;18(2):e245-e253. Go to original source... Go to PubMed...
    11. Magnuson A, Sedrak MS, Gross CP, et al. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol. 2021;39(6):608-618. Go to original source... Go to PubMed...
    12. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233-1241. Go to original source... Go to PubMed...
    13. Agresti R, Martelli G, Sandri M, Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer. 2014;120(6):885-893. Go to original source... Go to PubMed...
    14. Castelo M, Sutradhar R, Faught N, et al. The Association Between Surgical Axillary Staging, Adjuvant Treatment Use and Survival in Older Women with Early Stage Breast Cancer: A Population-Based Study. Ann Surg Oncol. 2023;30(7):3901-3912. Go to original source... Go to PubMed...
    15. Welsh JL, Hoskin TL, Day CN, et al. Predicting Nodal Positivity in Women 70 Years of Age and Older with Hormone Receptor-Positive Breast Cancer to Aid Incorporation of a Society of Surgical Oncology Choosing Wisely Guideline into Clinical Practice. Ann Surg Oncol. 2017;24(10):2881-2888. Go to original source... Go to PubMed...
    16. Kunkler IH, Williams LJ, Jack WJ, et al. PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266-273. Go to original source... Go to PubMed...
    17. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387. Go to original source... Go to PubMed...
    18. Martelli G, Boracchi P, Ardoino I, et al. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012;256(6):920-924. Go to original source... Go to PubMed...
    19. Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30(9):936-942. Go to original source... Go to PubMed...
    20. Collin LJ, Cronin-Fenton DP, Ahern TP, et al. Early Discontinuation of Endocrine Therapy and Recurrence of Breast Cancer among Premenopausal Women. Clin Cancer Res. 2021;27(5):1421-1428. Go to original source... Go to PubMed...
    21. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387. Go to original source... Go to PubMed...
    22. Meattini I, Poortmans PMP, Marrazzo L, et al. Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 - EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. J Geriatr Oncol. 2021;12(2):182-189. Go to original source... Go to PubMed...
    23. Whelan TJ, Smith S, Parpia S, et al. LUMINA Study Investigators. Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer. N Engl J Med. 2023;389(7):612-619. Go to original source... Go to PubMed...
    24. Carvalho ÍT, Rezende ACP, Bernardo RJC. Pros and cons of radiotherapy omission in elderly breast cancer patients following breast conservative surgery. Transl Cancer Res. 2020;9(Suppl 1):S236-S241. Go to original source... Go to PubMed...
    25. De-Escalation of Breast Radiation trial for hormone sensitive, HER-2 negative oncotype recurrence score less than or equal to 18 breast cancer (DEBRA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT04852887.
    26. Regional radiotherapy in biomarker low-risk node positive and T3N0 breast cancer (TAILOR RT). Available from: https://clinicaltrials.gov/ct2/show/NCT03488693.
    27. Reddy JP, Woodward W. Early-stagebreastcancer (ESBC) in: Pocketradiationoncology: the MD Anderson CancerCenter handbookofradiationoncology, edited by Chad Tang, AshanFarooqi. Philadelphia: WoltersKluwer; 2020.Další literatura u autorky a na www.onkologiecs.cz
    28. Donovan E, Bleakley N, Denholm E, et al. Breast Technology Group. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254-264. Go to original source... Go to PubMed...
    29. Hlavka A, Vanasek J, Odrazka K, et al. Tumor bed radiotherapy in women following breast conserving surgery for breast cancer-safety margin with/without image guidance. Oncol Lett. 2018;15(4):6009-6014. doi: 10.3892/ol.2018.8083. Epub 2018 Feb 16. PMID: 29556317; PMCID: PMC5844069. Go to original source... Go to PubMed...
    30. Meattini I, Becherini C, Boersma L, et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21-e31. Go to original source... Go to PubMed...
    31. START Trialists' Group; Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331-341. Go to original source... Go to PubMed...
    32. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086-1094. Go to original source... Go to PubMed...
    33. Whelan TJ, Pignol JP, Levine MN, Long-term results of hypo­fractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513-520. Go to original source... Go to PubMed...
    34. Vicini FA, Winter K, Freedman GM, et al. NRG RTOG 1005: A phase III trial of hypo fractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. Int J Radiat Oncol. 2022;114:S1. Go to original source...
    35. Liu L, Yang Y, Guo Q, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020;15(1):17. Go to original source... Go to PubMed...
    36. Hypofractionated radiation therapy after mastectomy in preventing recurrence in patients with stage IIA-IIIA breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT03414970.
    37. Murray Brunt A, Haviland JS, Wheatley DA, et al. FAST-Forward Trial Management Group. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613-1626. Go to original source... Go to PubMed...
    38. Spencer K, Jones CM, Girdler R, et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study. Lancet Oncol. 2021;22(3):309-320. Go to original source... Go to PubMed...
    39. Vicini FA, Kestin LL, Goldstein NS. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: a pathologic analysis. Int J Radiat Oncol Biol Phys. 2004;60(3):722-730. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.